Literature DB >> 17566119

Malignant Tourette syndrome.

Min-Yuen Cynthia Cheung1, Joohi Shahed, Joseph Jankovic.   

Abstract

The aim of this work was to draw attention to potentially life-threatening symptoms associated with Tourette syndrome (TS) and to explore their relationship to TS comorbidities. Medical records of all patients with TS evaluated at our Movement Disorders Clinic between July 2003 and July 2006 were reviewed. Data on patients with malignant TS, defined as >or=2 emergency room (ER) visits or >or=1 hospitalizations for TS symptoms or its associated behavioral comorbidities, were entered into a dataset and analyzed. Five illustrative cases are described. Of 333 TS patients evaluated during the 3-year period, 17 (5.1%) met the criteria for malignant TS. Hospital admission or ER visits were for tic-related injuries, self-injurious behavior (SIB), uncontrollable violence and temper, and suicidal ideation/attempts. Compared with patients with nonmalignant TS, those with malignant TS were significantly more likely to have a personal history of obsessive compulsive behavior/disorder (OCB/OCD), complex phonic tics, coprolalia, copropraxia, SIB, mood disorder, suicidal ideation, and poor response to medications. Although TS is rarely a disabling disorder, about 5% of patients referred to a specialty clinic have life-threatening symptoms. Malignant TS is associated with greater severity of motor symptoms and the presence of >or=2 behavioral comorbidities. OCD/OCB in particular may play a central role in malignant TS; obsessive compulsive qualities were associated with life-threatening tics, SIB, and suicidal ideation. Malignant TS is more refractory to medical treatment than nonmalignant TS. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17566119     DOI: 10.1002/mds.21599

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  38 in total

Review 1.  The genetics of Tourette syndrome.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2012-03-13       Impact factor: 42.937

2.  Tics status: a movement disorder emergency: observations.

Authors:  Norbert Kovacs; Robert Herold; Jozsef Janszky; Samuel Komoly; Ferenc Nagy
Journal:  J Neurol       Date:  2010-07-24       Impact factor: 4.849

3.  Mozart's movements and behaviour: a case of Tourette's syndrome?

Authors:  Aidin Ashoori; Joseph Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11       Impact factor: 10.154

4.  Pallidal Neurostimulation and Capsulotomy for Malignant Tourette's Syndrome.

Authors:  Chencheng Zhang; Hongxia Li; Yixin Pan; Haiyan Jin; Bomin Sun; Yiwen Wu; Li Dianyou
Journal:  Mov Disord Clin Pract       Date:  2019-04-05

Review 5.  Systematic review of severity scales and screening instruments for tics: Critique and recommendations.

Authors:  Davide Martino; Tamara M Pringsheim; Andrea E Cavanna; Carlo Colosimo; Andreas Hartmann; James F Leckman; Sheng Luo; Alexander Munchau; Christopher G Goetz; Glenn T Stebbins; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2017-01-10       Impact factor: 10.338

Review 6.  Updates in medical and surgical therapies for Tourette syndrome.

Authors:  Irene A Malaty; Umer Akbar
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

7.  Treatment of Tourette syndrome.

Authors:  Roger M Kurlan
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

8.  DBS in Dystonia and Other Hyperkinetic Movement Disorders.

Authors:  A Barbey; J Bloch; F J G Vingerhoets
Journal:  Curr Treat Options Neurol       Date:  2015-09       Impact factor: 3.598

9.  Consanguineous Iranian kindreds with severe Tourette syndrome.

Authors:  Maria G Motlagh; Arshia Seddigh; Behnoosh Dashti; James F Leckman; Javad Alaghband-Rad
Journal:  Mov Disord       Date:  2008-10-30       Impact factor: 10.338

10.  Suicidal ideation in youth with tic disorders.

Authors:  Carly Johnco; Joseph F McGuire; Nicole M McBride; Tanya K Murphy; Adam B Lewin; Eric A Storch
Journal:  J Affect Disord       Date:  2016-04-23       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.